DDX11 and renal cell carcinoma: Importantly, DDX11 knockdown also significantly induced sensitivity to PARPi by Olaparib compared to Olaparib alone, pointing towards DDX11 as a biomarker for PARP therapy in renal cell carcinoma [106].